Clinical Trial Update: Vedolizumab, Anti-CD25 Antibody, Rapid Reduction of Glucocorticoids for SR-aGVHD With Gastrointestinal Involvement [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating vedolizumab and an anti-CD25 antibody for rapid reduction of glucocorticoids in steroid-refractory acute graft-versus-host disease with…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease
• Steroid-refractory Acute Graft-versus-host Disease

Drugs mentioned

• Vedolizumab (vedolizumab)
• anti-CD25 antibody (cd25-targeting antibody)

Snippet

Sponsor: The First Affiliated Hospital of Soochow University | Conditions: Safety and Efficacy | Phase 4 | Status: UNKNOWN